Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Highly awaited Alzheimer's drug hit by delays retrieved 9 March 2024 from https://medicalxpress.com/news/2024-03-highly-awaited-alzheimer-drug-delays.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
The battle over the trillion-dollar weight-loss bonanzaNovo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?
Weiterlesen »
Palworld dev says highly-requested feature ‘isn’t possible’ on Steam or XboxPalworld developer Pocketpair says a highly-requested feature 'isn't possible' on Steam or Xbox for the time being.
Weiterlesen »
A fresh truce between Israel and Hamas could be highly significantAll parties involved in talks are making positive noises that a deal can soon be reached - but nothing can be taken for granted at this stage.
Weiterlesen »
Multi-donor HEPATOPAC® cultures for highly efficient in vivo predictionsMulti-donor HEPATOPAC® cultures allow for an experimental design in which data is obtained concurrently from pooled human donors in a single experiment.
Weiterlesen »
FDA delays decision on new Alzheimer's drugInstead of approving the new Alzheimer's drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely by an expert panel, the drug's maker said Friday.
Weiterlesen »
Unlocking Alzheimer's secrets: Study pinpoints APOE4's harmful effect on lipidsUNC School of Medicine researcher Sarah Cohen, PhD, and Ian Windham, a former PhD student from the Cohen lab, have made a new discovery about apolipoprotein E (APOE) – the biggest genetic risk factor for late-onset Alzheimer's disease.
Weiterlesen »